Show results for
Refine by
Phase 1 Clinical Suppliers Serving Mongolia
60 companies found
based inGangnam-gu, SOUTH KOREA
Kangstem Biotech promotes a step-by-step business strategy to optimize its success rate of new global medicine development. Kangstem Biotech will create a world where people can enjoy a healthy and happy life by developing stem cell therapeutic ...
based inYongin-si, SOUTH KOREA
Vivozon is a global innovative drug development company established in 2008. We built an efficacy-based new drug discovery system that is clearly distinct from the existing new drug development paradigm, and discovered the non- narcotic analgesic ...
Opiranserin (VVZ-149) for injection is a first-in-class non-narcotic analgesic under development by Vivozon. As atreatment for postoperative pain used as a first-line therapy in the global market, Opiranserin aims to ultimately replaceopioid ...
based inNorth Brunswick, NEW JERSEY (USA)
Ascendia Pharmaceutical Solutions specializes in comprehensive drug development services, providing tailored formulation and manufacturing solutions from pre-formulation stages to commercialization. With a focus on overcoming pharmaceutical ...
based inRavensburg, GERMANY
Vetter is an international specialist in the production of aseptically prefilled syringe systems, cartridges and vials. We are a family-owned, independent company and do not manufacture our own drugs. Our focus is on providing highly skilled support ...
Explore how we transform your API into a supply of high-quality clinical material for your ...
based inOxford, UNITED KINGDOM
Founded in 2012, we are the leading pharmatech company and the first to automate drug discovery. As a full stack AI drug discovery company, we generate our own data before combining the analytical power of AI with the creativity and expertise of our ...
EXS21546 is our peripherally-restricted and selective antagonist of the Adenosine A2a Receptor. It is designed for anti-cancer immunotherapy, combatting adenosine related immunosuppressive effects, through T-cell ...
based inBox Hill North, AUSTRALIA
Magellan is a private Australian company with expertise in research, development and manufacturing of stem cells for the treatment of osteoarthritis. We lead the way globally in scientific, clinical and commercial expertise for stem cell supply and ...
Our product MAG200 has successfully completed Phase I/II of a clinical trials on the use of allogeneic (donor) off-the-shelf stem cell therapy for OA. The pivotal Phase III trial is planned to commence 2023. ...
based inStockholm, SWEDEN
Gesynta Pharma is a Swedish pharmaceutical company that develops unique drug candidates with the aim to reduce harmful inflammation and increase blood flow in the body’s microvasculature, thereby providing safe and efficacious treatments for several ...
GS-248 is Gesynta Pharma’s most advanced drug candidate, currently in clinical development as a potential treatment of systemic sclerosis. Recent clinical phase I data in healthy individuals show that GS-248 potently inhibits the production of ...
based inAnn Arbor, MICHIGAN (USA)
BlueWillow Biologics is a clinical-stage, privately-held biopharmaceutical company focused on developing and commercializing intranasal vaccines using its patented nanoemulsion platform. The platform, originally discovered at the University of ...
BlueWillow’s vaccine technology incorporates nano-scale droplets that are manufactured at an average size of 400–500 nanometers to deliver and adjuvant a broad spectrum of ...
based inDieppe, NEW BRUNSWICK (CANADA)
Triple Hair aims to be a global leader in clinical research for Androgenetic Alopecia and is making great strides in developing solutions for thinning hair and hair loss with successful dense regrowth. After testing all known hair loss treatments ...
This innovative triple combination therapy promotes hair regrowth in men with androgenic alopecia. Its exclusive combination of molecules acts at various stages of the hair growth cycle to stop hair loss and stimulate regrowth, while also making ...
based inGarching / Munich, GERMANY
ITM Isotope Technologies Munich SE is a privately owned biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes ...
based inPhiladelphia, PENNSYLVANIA (USA)
Neuraptive Therapeutics, Inc. is a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by peripheral nerve injuries. The Company’s franchise ...
based inBerlin, GERMANY
MerLion Pharmaceuticals is a biopharma company focusing on the research and development of drugs for the treatment of serious bacterial infections. MerLion - located in Berlin-Buch, Germany - manages the non-clinical and clinical development as well ...
based inGroningen, NETHERLANDS
ViciniVax is a Dutch clinical stage biopharmaceutical company. It is a spin-off from the University Medical Center Groningen, the Netherlands, developing therapeutic cancer vaccines. Our first product candidate Vvax001, a therapeutic cancer vaccine ...
based inJupiter, FLORIDA (USA)
Dyadic International, Inc. (NASDAQ: DYAI) is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and ...
We are building an active pipeline of products for human health by applying our proprietary and patented C1 technology to develop vaccines and antibodies for infectious and other diseases. Vaccine Development: The C1 platform is ready for full ...
based inVancouver, BRITISH COLUMBIA (CANADA)
RepliCel is a regenerative medicine company focused on aesthetics and orthopedics. Our cell therapy products are tailor-made to restore cellular function to rejuvenate aging or sun damaged skin, regrow hair, and repair tendons. Our next-generation ...
RCT-01 is a proprietary autologous cell therapy being developed to treat chronically damaged tendons. * *This product is currently in clinical testing and not yet commercially available. RCT-01 is an autologous cell therapy utilizing non-bulbar ...
based inTel-Aviv, ISRAEL
RedHill Biopharma (NASDAQ: RDHL) is driven to develop extraordinary medicines for people to live extraordinary lives. RedHill applies innovation, focus and a collective mindset of delivering on our promises, to build a company at the forefront of ...
Opaganib (ABC294640) is a first-in-class, proprietary sphingosine kinase-2 (SK2) selective inhibitor, administered orally, with anticancer, anti-inflammatory and anti-viral ...
based inSunrise, FLORIDA (USA)
U.S. Stem Cell, Inc. (OTC:USRM) is an emerging leader in the worldwide development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions. Based in Sunrise, Florida, the Company has developed a clinical ...
based inRichmond, BRITISH COLUMBIA (CANADA)
BioMark is an oncology-focused company with advanced near-to- market liquid biopsy diagnostic technologies. Our technology improves patient comfort, outcomes and early cancer detection. Biomark owns various intellectual properties, developed for the ...
based inSeattle, WASHINGTON (USA)
Nexelis is your partner for assay and biomarker development, advanced bioanalytical and laboratory testing, and translational immunology. As the leading specialty laboratory, we have unrivaled expertise in immunology, specifically in the areas of ...
Custom Assay Development to Advance Molecules. You need reliable approaches to support what’s next in your development programs whether they are complex small molecules, advanced biologics, or vaccines. At Nexelis, a Q² Solutions Company, ...
based inTurku, FINLAND
Biovian is a Bio-CDMO that provides services to biotech companies developing innovative gene therapies or biopharmaceuticals. Our goal is to turn ideas into products by taking client projects from the laboratory bench to the clinic. To do so we ...
The state-of-the-art production facility allows for flexible viral vector production scenarios. The cleanroom class C (EU GMP) and biosafety level 2 facility is designed for the manufacturing of GMP-grade viral vectors. The space design follows a ...